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ABSTRACT 
 
Objective: To examine the effects of aerobic exercise or vitamin B supplementation on cognitive 
function in older adults with mild cognitive impairment (MCI).  
Design: Randomized placebo-controlled trial. 
Setting: General community. 
Participants: community-dwelling adults aged 70-80 with MCI.                                                                
Interventions: The 152 participants were randomly assigned to two interventions: 1) a twice-
weekly, group-based, moderate-intensity walking program (WP, n=77) or a low-intensity placebo 
activity program (n=75) for one year; and 2) daily vitamin pill containing 5 mg folic acid, 0.4 mg 
vitamin B12, 50 mg vitamin B6 (FA/B12/B6, n=78) or placebo-pill (n=74) for one year.  
Outcome measures: Cognitive function, measured with neuropsychological tests at baseline and 
after six and 12 months.  
Results: Median session attendance to the exercise programs (25th-75th percentile) was 63 (2-
81) percent and median compliance with taking pills (25th-75th percentile) was 100 (99-100) 
percent. Gender was an effect-modifier. Intention-to-treat analysis revealed no main intervention 
effect for either intervention. In women in the WP, attention (Stroop combination task) improved 
by 0.3 seconds (p=0.04) and memory (auditory verbal learning test) by 0.04 words (p=0.06) with 
each percent increase in session attendance. In men attending at least 75 percent of the sessions, 
the WP improved memory (beta [95%CI]= 1.5 [0.1; 3.0] words).  
Conclusion: The walking program and/or FA/B12/B6 supplementation were not effective in 
improving cognition within one year. The walking program, however, was efficacious in 
improving memory in men and memory and attention in women with better adherence.  
Trial Registration: International Standard Randomized Controlled Trial Number Register, 
19227688, http://www.controlled-trials.com/isrctn/. 
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INTRODUCTION  
 
Cognitive impairment is an important public health concern, since the number of elderly people 
with age-related health problems, such as cognitive decline and dementia, is growing 
considerably. Research on potentially effective interventions for preventing the progression of 
cognitive impairment is therefore warranted, and physical exercise and vitamin B 
supplementation are promising and relatively inexpensive interventions. 
 
Regular exercise is associated with better cognitive function and delayed onset of Alzheimer’s 
disease,
1-4
 and has been shown to improve cognitive function in cognitively healthy and 
demented older adults.
5;6
 The specific mechanisms of exercise beneficially affecting cognitive 
performance in subjects in different stages of cognitive decline are not yet known. A recent study 
of 59 sedentary adults aged 60-79 years has shown that six months of aerobic training increased 
brain volume in regions of the brain associated with age-related decline in cognition, compared 
with non-aerobic training.
7
 Improvement of vascularisation and increased blood flow to the brain 
are other possible pathways, which may be promoted by improving aerobic fitness.
8;9
 
 
Vitamin B supplementation may also affect cognitive function through its effect on 
homocysteine,
10
 which is associated with impaired cognition.
11-16
 There have however been few 
methodologically sound trials on the effect of vitamin B supplementation on cognition.
17-19
 
Vitamin B supplementation may affect cognitive performance via two mechanisms.
20
 First, 
vitamin B is needed to transform homocysteine into methionine, which is an essential amino acid 
for the central nervous system. Lack of methionine results in disorders in neurological and 
psychological status. Second, vitamin B may beneficially influence homocysteine concentrations, 
resulting in structural vascular changes in the brain. 
 
This paper describes the effects of two interventions on cognitive performance in a sample of 
community-dwelling older adults with mild cognitive impairment (MCI). MCI is a potential 
transitional stage between normal cognitive function and Alzheimer’s Disease, in which people 
experience memory loss to a greater extent than is expected for age and education, but do not 
meet criteria for Alzheimer’s disease.21 The interventions were: 1) one year of a moderate 
intensity walking program designed to improve aerobic fitness; and 2) one year of daily 
supplementation with folic acid, vitamins B12 and B6. It was hypothesized that both 
interventions would beneficially influence cognitive performance.  
 
METHODS  
 
Study design  
The study was a double-blind randomized controlled trial (RCT). A two by two factorial design 
was used to compare the effects of: 1) a walking program with a placebo activity program; and 2) 
vitamin B supplementation with placebo-supplementation in a single sample. Thus, half of the 
subjects in the walking program got vitamin B supplements and the other half got placebo 
supplements. This was also the case within the placebo activity program. This design allows two 
hypotheses to be tested at the same time, by randomizing subjects to two interventions and 
adjusting the results from each intervention for the effects of the other.
22;23
 The medical ethics 
committee approved the study-protocol.
24 
All participants gave written informed consent.  
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Participants 
All community-dwelling inhabitants aged 70 to 80 years in a Dutch town (n=5491) were sent an 
invitation letter in September 2003. Among those willing to participate, inclusion criteria were 
checked using a two-step screening consisting of a postal questionnaire and a telephone 
interview.
25
 The operational criteria for MCI and additional inclusion criteria for the trial are 
described in Table 1. 
 
Table 1 Inclusion and exclusion criteria for participation in the trial  
 
Operationalisation of Petersen criteria for MCI (1-5) and additional inclusion criteria for the 
RCT (6-12) 
1. Memory complaints (answer ‘yes’ to question ‘do you have memory complaints’, or at least 
twice answering ‘sometimes’ on the Strawbridge cognition scale 26) 
2. Objective memory impairment (10 WLT
27
 delayed recall ≤ 5 and percentage savings ≤ 100) 
3. Normal general cognitive function ( TICS
28
 ≥ 19 and MMSE29 ≥ 24) 
4. Intact daily functioning (no report of disability in activities of daily living on GARS-scale
30
, 
except on the item ‘taking care of feet and toe nails’) 
5. Absence of dementia (TICS
28
 ≥ 19  and MMSE29 ≥ 24) 
6. Being able to perform moderate intensity physical activity, without making use of walking 
devices, e.g. a rollator or a walking frame  
7. Not using vitamin supplements/ vitamin injections/ drinks with folic acid, vitamins B12 and 
B6, comparable to the vitamin supplement given in the intervention 
8. Not suffering from epilepsy, multiple sclerosis, Parkinson’s disease, kidney disorder 
requiring haemodialysis, psychiatric impairment 
9. Not suffering from depression as measured by the GDS
31(cut off ≤ 5) 
10. Not using medication for rheumatoid arthritis or psoriasis which interfered with the vitamin 
supplement 
11. No alcohol abuse (men < 21 drinks a week, women < 15 drinks a week) 
12. Not currently living in a nursing home or on a waiting list for a nursing home 
 
MCI= Mild Cognitive Impairment; RCT= Randomized Controlled Trial; 10 WLT= 10 Word 
Learning Test; TICS= Telephone Interview for Cognitive Status; MMSE= Mini Mental State 
Examination; GARS= Groningen Activity Restriction Scale; GDS=Geriatric Depression Scale 
 
Randomization and blinding 
After the baseline interview, participants were randomized using the option ‘random sample of 
cases’ in SPSS. Randomization was stratified for physical activity level assessed by the LASA 
physical activity questionnaire.
32
 Participants were randomized to: 1) walking program or 
placebo activity program; then within each activity program subjects were randomized to: 2) 
vitamin B supplementation or placebo supplementation. Participants and exercise instructors 
were blinded to group allocation by being left unaware of which exercise program was supposed 
to be effective. The pills were coded as A or B by the manufacturer. The key was decoded after 
data-analysis. All cognitive outcome measures were assessed by trained examiners, who were 
also blinded to group allocation.  
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Interventions 
Walking program (WP) and Placebo Activity program (PAP) 
Both the WP and the PAP were group-based and lasted one year (June 2004 – June 2005). 
Trained instructors supervised exercise sessions twice-weekly for one hour. Adherence was 
defined as the percentage of attended sessions.  
 
The WP was based on an existing aerobic walking program designed to improve aerobic fitness,
33
 
and intensity was moderate (> 3 metabolic equivalents). Each session consisted of a warm-up, 
moderate-intensity walking exercises and cool-down. The instructors monitored exercise 
intensity during all sessions subjectively – e.g. participants were still able to talk, but also showed 
signs of moderate intensity activity, such as increased breathing frequency. Walking-pace and 
distance increased gradually during the program. Sessions took place outdoors in municipal 
parks. 
 
The PAP, developed by experienced exercise instructors, consisted of an introduction, low-
intensity (<3 metabolic equivalents) non-aerobic group exercises and a closing. Sessions included 
relaxation, activities of daily living, balance, flexibility and postural exercises. The PAP was 
carried out in community centres. 
 
Vitamin B supplementation (FA/B12/B6) and placebo supplementation 
Participants randomized to FA/B12/B6-supplementation received one pill daily, containing 5 mg 
vitamin B11 (Folic Acid), 0.4 mg vitamin B12 (Cyanocobalamin) and 50 mg vitamin B6 
(Pyridoxine-hydrochloride) for a year. These vitamin supplements are available on prescription in 
The Netherlands. For the purpose of this study, the package and vitamin pills could not be 
identified as an existing supplement. Participants in the control group received an identical-
looking placebo-pill. Pills were packed in one-week blister packs labelled for each day of the 
week. Compliance was verified by counting pills in returned blister packs. 
 
Measures 
Measurement of baseline variables is described in detail elsewhere.
24
 Cognitive measures were 
collected at baseline and after six and 12 months during a standardized interview. The Mini 
Mental State Examination (MMSE) was used to measure general cognitive function for 
descriptive purposes. The maximum score is 30, and a score below 24 was considered 
abnormal.
29
 Four other tests were administered to assess different aspects of cognition:  
- Memory by the Auditory Verbal Learning Test (AVLT) (immediate and delayed recall; 
maximum scores 75 and 15 words, respectively).
34
  
- Executive function by the verbal fluency test (VFT). Participants were asked to name words 
starting with a particular letter during a one-minute period. In each administration of the test, 
three letters were given. The score was the total number of named words.
35
 
- Information processing speed by the Digit Symbol Substitution Test (DSST). The participant 
was asked to draw symbols corresponding to nine digits below numbered boxes during a 90-
second period. The score was the number of correctly drawn symbols.
36
 
- Attention by the Abridged Stroop Colour Word Test (SCWT-A). The SCWT-A consists of three 
tasks; 1) reading eight rows of five written colours; 2) naming the colours of eight rows of five 
red, green, blue or yellow coloured rectangles; 3) naming the colour of ink for the words red, 
green, blue or yellow. The score was the time needed to complete each task.
37
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Statistical analysis 
Sample size 
Since participants were selected on the basis of memory complaints and impairments, memory 
was considered the most important cognitive outcome in our study. Therefore, sample size 
calculations were based on AVLT data.
21
 The average difference between subjects with MCI and 
mild Alzheimer’s disease and subjects with MCI and Alzheimer’s disease for immediate recall 
was five words. On the basis of this difference, it was estimated that 136 participants would be 
required (α = 0.05 and β = 0.80). To allow for a drop-out of 25 percent, the final sample size was 
179 participants.  
 
Data analysis 
Differences in baseline characteristics between intervention and control groups (e.g. WP versus 
PAP and FA/B12/B6 versus placebo) were tested using independent t-tests, Mann Whitney U 
tests and chi-square tests. For both interventions, data were analyzed on a modified intention-to-
treat basis, including participants with at least one post-baseline assessment. Longitudinal 
regression analysis was used to assess changes in each outcome measure. The two follow-up 
measurements were defined as dependent variable and multi-level analysis with two levels was 
used, 1) time of follow-up measurement (values corresponding with performance after six and 12 
months intervention); 2) individual. Reported regression coefficients indicate differences between 
WP and PAP, or FA/B12/B6-supplementation and placebo-supplementation. Data were analyzed 
using crude and adjusted models. In the crude models, the independent variables were exercise 
intervention, vitamin intervention and baseline performance. In the adjusted models, education, 
baseline activity level, baseline vitamin status, adherence to the exercise program and compliance 
with the supplementation were added as covariates. Effect modification by gender was checked. 
Because gender was an effect modifier in four of seven outcome measures, analyses for all 
outcomes were stratified by gender.  
 
Since adherence with the WP and the PAP was sub-optimal, a post-hoc analysis was performed 
to check for effect modification by session attendance. Finally, a per protocol analysis, including 
only participants who attended at least 75 percent of the exercise sessions was performed. This 
cut-off point is in concordance with previous exercise intervention studies in elderly people.
39;40 
Data were analyzed using SPSS (release 12.0.2). A significance level of five percent was used for 
between-group comparisons and of ten percent for interaction terms.   
 
RESULTS   
 
Participant flow and characteristics 
After baseline measurement, 179 participants were randomized. Twenty-seven of them were 
excluded from the analysis, because they only provided baseline data (Figure 1). Compared with 
the remaining 152 participants, a higher percentage of these 27 participants was married (71 
versus 52 percent, p=0.05), and fewer were current smokers (0 versus 14 percent, p=0.04). No 
significant differences existed between measures of cognition. Baseline variables for men and 
women are shown in Table 2. Participants in the WP did not differ significantly from participants 
in the PAP. In the FA/B12/B6-supplementation group, a higher percentage of men had lower 
education and a higher percentage of women had intermediate/high education compared with the 
placebo-supplementation group.  
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PAP: n= 93 
lost to follow-up: n=18*                        
   - illness: n=8 
   - illness SO: n=1 
   - too busy: n=4 
   - location too far: n=1 
   - died: n=1 
   - other: n=3 
discontinued PAP: n=19 
   - illness: n=2 
   - illness SO: n=2 
   - too intensive: n=1 
   - too busy: n=7 
   - location too far: n=2 
   - other: n=5 
WP: n= 86 
lost to follow-up: n=9* 
   - illness: n=6 
   - illness SO: n=1 
   - too busy: n=1 
   - location too far: n=1 
discontinued WP: n=28                  
   - illness: n=14 
   - illness SO: n=1 
   - too intensive: n=5 
   - too light: n=1 
   - too busy: n=3 
   - location too far: n=2 
   - other: n=2 
T6: n= 77† 
lost to follow-up: n=6 
   - illness: n=3 
   - other: n=3 
discontinued WP: n=5 
   - illness: n=5 
T6: n= 75† 
lost to follow-up: n=8 
   - illness: n=7 
   - other: n=1 
discontinued PAP: n=1 
   - illness: n=1 
T12: n= 71 T12: n= 67 
Analysed: n= 77 Analysed: n= 75 
FA/B6/B12: n= 90 
lost to follow-up: n=12* 
   - illness: n=6  
   - illness SO: n=1 
   - too busy: n=1                              
   - other: n=4 
discontinued pills: n=2 
placebo pills: n= 89 
lost to follow-up: n=15* 
   - illness: n=8  
   - illness SO: n=1 
   - too busy: n=4 
   - other: n=1 
   - died: n=1 
discontinued pills: n=9 
T6: n= 74† 
lost to follow-up: n=7 
   - illness: n=4 
   - other: n=3 
discontinued pills: n=1 
T12: n= 67 T12: n= 71 
Analysed: n= 78 Analysed: n= 74 
T6: n= 78† 
lost to follow-up: n=7           
   - illness: n=6 
   - other: n=1 
discontinued pills: n=3 
selected for baseline measurement: n=209 
drop-out: n= 12 
   - not meeting inclusion criteria: n=6 
   - too busy: n=3 
   - bad vision: n=2 
   - unknown: n=1 
Randomisation: n= 179 
 
complete baseline data available: n= 191 
drop-out: n= 18 
   - withdrew after further information: n=16 
   - baseline data not complete: n=2 
- TI: n= 412 
- no TI: n= 128 
- eligible for TI: n= 540 
- not eligible for TI (not meeting 
inclusion criteria questionnaire): n=947 
willing to participate: n= 1487 
- MCI: n= 209 
- no MCI: n= 203 
source population (community-
dwelling adults, age 70-80): n= 5491 
two step 
population 
screening 
Intervention 1: WP versus PAP Intervention 2: FA/B12/B6 versus Placebo 
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Figure 1 Flow Chart  
TI= Telephone Interview; MCI= Mild Cognitive Impairment; WP= Walking Program; PAP= 
Placebo Activity Program; FA/B12/B6= Folic Acid, vitamins B12 and B6; SO= Significant 
Other; T6= Follow-up after 6 months; T12= Follow-up after 12 months; * Excluded from 
analysis (only baseline data available); 
†
 Included in analysis
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Table 2 Baseline characteristics of the study population by intervention group (n=152)  
 
 Walking Program vs. Placebo Activity Program FA/B12/B6 vs. placebo pills 
 Men Women Men Women 
 WP (n=37) PAP (n=48) WP (n=40) PAP (n=27) vit B (n=44) placebo 
(n=41) 
vit B (n=34) placebo 
(n=33) 
Age (Mean (SD)) 74 (2.7) 75 (2.8) 76 (2.9) 75 (2.9) 75 (2.7) 74 (2.9) 76 (2.9) 76 (2.9) 
MMSE (Median (25
th
; 75
th
 ‰)) 29 (28; 29) 29 (28; 29) 29 (28; 29) 29 (28; 30) 28 (28; 29) 29 (28; 29) 29 (29; 30) 29 (28; 30) 
% low/ intermediate/ high education 
a
 57/ 16/ 27 42/ 35/ 23 64/28/8 70/ 19/ 11 61/ 21/ 18 * 34/ 34/ 32 52/ 33/ 15 * 82/ 15/ 3 
% living with partner 87 85 50 56 82 90 53 52 
PA, min/day (Median (25
th
; 75
th
 ‰)) b 79 (63; 137) 79 (36; 124) 53 (42; 80) 48 (33; 110) 77 (55; 125) 81 (35; 125) 55 (41; 89) 51 (33; 80) 
% deficient FA/B12/B6 
c
 35/ 5/ 0 42/ 6/ 0 55/ 10/ 0 59/ 11/ 0 39/ 7/ 0 39 / 5/ 0 62/ 12/ 0 52/ 9/ 0 
% hyperhomocysteinemia
 d
 27 33 20 15 32 29 21 15 
% hypertension
 e
 19 32 8 19 30 22 18 7 
BMI, kg/m2 (Mean (SD)) 26.5 (3.4) 26.9 (3.1) 26.7 (3.0) 28.3 (4.0) 27 (3.4) 26.5 (3.0) 27.5 (3.9) 27.5 (3.0) 
% smokers 11 15 15 15 18 7 15 16 
 
WP= Walking Program; PAP= Placebo Activity Program; FA/B12/B6= Folic Acid, vitamins B12 and B6; MMSE= Mini Mental State 
Examination; PA= Physical Activity; BMI= Body Mass Index;
 a 
low= no education, primary education, lower vocational training, 
intermediate= intermediate level secondary education, intermediate vocational training, high= higher level secondary education, higher 
vocational training, university training; 
b
 ≥ 3.0 metabolic equivalents; c cut off points: FA red blood cell < 305 nmol/L or FA plasma 
<6,3 nmol/L, B12 ≤ 150 pmol/L, B6 < 20 nmol/L; d homocysteine > 14 mmol/L; e hypertension= diastole ≥ 90 and systole ≥ 160;  
* Significant difference between FA/B12/B6 and placebo-supplementation (p<0.05)
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Adherence and compliance 
Thirty participants, 19 men and 11 women, did not attend a single session, but were included in 
the intention-to-treat analysis. Median adherence (25
th
 – 75th percentile) to both exercise 
programs, including these participants, was 63 (2-81) percent and did not differ between groups. 
At baseline, adherent men attending at least 75 percent of the sessions (n=33) were more often 
living with a partner (82% versus 65%, p=0.03) and reported to be less physically active than 
non-adherent men (n=52), (median [25
th
 -75
th
 percentile] was 64 [32-82] versus 87 [34-139] 
minutes/day, p=0.04). Only 18 women attended at least 75 percent of the sessions. The most 
frequent reasons for drop-out from the exercise programs after the start were health-related 
problems. No adverse events of the WP or PAP were reported.  
 
Median compliance (25
th
 –75th percentile) with the (vitamin) supplementation was 100 (99-100) 
percent. Two participants stopped taking vitamin FA/B12/B6-pills after reporting adverse side 
effects, i.e. sleep problems and increased forgetfulness; one participant discontinued the placebo-
pills after reporting not feeling well.  
 
Intention-to-treat analysis  
In the intention to treat analysis (Table 3), no significant main effect of walking or FA/B12/B6-
supplementation was found in men. In women, a beneficial main intervention effect of 
FA/B12/B6-supplementation was found on the DSST (beta [95%CI]= 2.9 [0.6; 5.3] symbols, 
p=0.02). Appendix Tables 1 and 2 present cognitive performance at baseline and after six and 12 
months intervention. 
 
Per protocol analysis 
In women, an interaction was observed between the exercise programs and adherence. With each 
percentage increase in session attendance, in the WP, the SCWT-A combination task 
performance improved by 0.3 seconds (p=0.04), and the AVLT delayed recall score improved by 
0.04 words (p=0.06). No interaction was observed in men. However, in men attending at least 75 
percent of the sessions (n=33), the WP beneficially affected AVLT delayed recall (beta 
[95%CI]= 1.5 [0.1; 3.0] words, p=0.04). The number of women attending at least 75 percent of 
the sessions (n=18) was insufficient to perform a reliable per protocol analysis.  
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Table 3 Effect of the two interventions on change in cognition (adjusted model) 
 
WP= Walking Program; PAP = Placebo Activity Program; FA/B12/B6= Folic Acid, vitamins B12 and B6; AVLT= Auditory Verbal 
Learning Test; SCWT-A= Stroop Colour Word Test- Abridged; s= seconds; DSST= Digit Symbol Substitution Test; VFT= Verbal 
Fluency Test; 
a
 Higher score indicates better performance; 
b 
Lower score indicates better performance;
 c  the beta’s (95 % CI) indicate 
the difference in outcome between the walking program and the placebo activity program or between the vitamin pills and the placebo-
pills: the unit is the unit of the outcome measure; * Significant difference between FA/B12/B6 and placebo
 Walking Program vs. Placebo Activity Program FA/B12/B6 vs. placebo pills 
 Men 
(WP: n=37 vs. PAP : n=48) 
Women 
(WP: n=40 vs. PAP: n=27) 
Men 
(vit B: n=44 vs. placebo: n=41) 
Women 
(vit B: n=34 vs. placebo: n=33) 
Outcome (unit) Beta (95%CI)
 c
 p-value Beta (95%CI)
 c
 p-value Beta (95%CI)
 c
 p-value Beta (95%CI)
 c
 p-value 
AVLT 1-5 (words)
 a
 -1.4 (-4.1; 1.3) 0.31 -0.6 (-3.8; 2.6) 0.72 -2.2 (-5.1; 0.6) 0.12 -0.1 (-3.4; 3.3) 0.97 
AVLT 6 (words)
 a
 -0.2 (-1.0; 0.6) 0.58 -0.4 (-1.6; 0.9) 0.56 -0.5 (-1.3; 0.3) 0.25 0.0 (-1.3; 1.3) 0.99 
SCWT-A task 1 (s)
 b
 0.6 (-0.6; 1.8) 0.29 -1.3 (-2.9; 0.3) 0.10 0.0 (-1.3; 1.2) 0.98 -0.9 (-2.6; 0.7) 0.27 
SCWT-A task 2 (s) 
b
 -1.0 (-2.2; 0.2) 0.10 0.6 (-0.9; 2.1) 0.46 0.1 (-1.1; 1.4) 0.84 -0.7 (-2.2; 0.9) 0.39 
SCWT-A task 3 (s)
 b
 0.9 (-6.8; 8.7) 0.81 -4.1 (-13.3; 5.2) 0.38 3.1 (-5.1; 11.3) 0.45 -1.1 (-10.8; 8.7) 0.83 
DSST (symbols)
 a
 0.9 (-1.2; 3.0) 0.40 0.8 (-1.4; 3.1) 0.47 -1.4 (-3.7; 0.8) 0.20 2.9 (0.6; 5.3) 0.02* 
VFT (words)
 a
 -1.7 (-4.4; 1.0) 0.21 -1.4 (-4.8; 2.0) 0.42 0.8 (-2.0; 3.6) 0.58 -1.0 (-4.5; 2.6) 0.59 
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Appendix Table 1 Cognitive test performance at baseline and after six and 12 months in the walking program and the placebo  
activity program (mean (SD), unless indicated otherwise) 
 
WP= Walking Program; PAP= Placebo Activity Program; AVLT= Auditory Verbal Learning Test; SCWT-A= Stroop Colour Word 
Test- Abridged; s= seconds; DSST= Digit Symbol Substitution Test; VFT= Verbal Fluency Test;
 a
 Higher score indicates better 
performance; 
b 
Lower score indicates better performance; 
c 
Median (25
th
; 75
th
 percentiles)
 Men  in WP Men in PAP Women in WP Women in PAP 
Outcome (unit) T0 (n=37) T6 (n=37) T12 (n=36) T0 (n=48) T6 (n=48 T12 (n=45) T0 (n=40) T6 (n=40) T12 (n=35) T0 (n=27) T6 (n=27) T12 (n=22) 
MMSE (points) 
 a, c 29 (28; 29) 28 (28; 29) 28 (27; 29) 29 (28; 29) 28 (27; 29) 28 (28; 29) 29 (28; 29) 28 (28; 29) 29 (27; 29) 29 (28; 30) 29 (27; 30) 29 (27; 30) 
AVLT 1-5 (words)
 a
 32.7 (7.8) 33.7 (10.8) 30.1 (9.4)
 
 30.4 (6.9) 33.2 (9.1)
 
 30.3 (9.0) 34.6 (8.2) 34.2 (11.1) 32.1 (9.0) 34.3 (8.3) 34.7 (7.6) 33.0 (7.7) 
AVLT 6 (words)
 a
 5.9 (2.5) 6.2 (3.0) 5.1 (2.9)
 
 5.3 (2.3) 6.3 (3.1)
 
 4.7 (2.6)
 
 6.3 (2.6) 6.2 (3.6) 5.6 (3.0) 6.0 (2.3) 6.5 (3.1) 5.5 (2.7) 
SCWT-A task 1 (s)
 b
 19.1 (3.8) 19.3 (4.3) 20.1 (4.7) 19.3 (3.6) 19.3 (4.6) 18.8 (3.9) 21.1 (5.8) 20.6 (5.4) 19.9 (4.7) 20.2 (3.5) 20.4 (4.3) 21.4 (4.2) 
SCWT-A task 2 (s)
 b
 25.4 (4.2) 25.1 (5.1) 25.0 (4.8) 25.3 4.9) 25.6 (5.6) 26.1 (5.3)
 
 26.5 (5.7) 26.9 (6.1) 25.4 (5.3) 26.0 (5.1) 24.7 (4.8) 25.4 (4.1) 
SCWT-A task 3 (s)
 b
 60.5 (20.0) 65.4 (25.7) 57.9 (14.0) 59.0 (18.8) 62.1 (30.9) 58.4 (22.1) 63.2 (22.1) 64.7 (24.4) 60.7 (25.3) 65.6 (20.0) 71.2 (33.4) 65.2 (24.8) 
DSST (symbols)
 a
 35.5 (10.7) 36.4 (10.4) 35.5 (10.0) 38.6 (10.0) 38.8 (9.5) 38.4 (11.3) 34.7 (9.7) 35.0 (9.9) 35.5 (9.6) 35.5 (10.5) 35.2 (12.6) 34.4 (8.6) 
VFT (words)
 a
 30.4 (9.9) 31.7 (8.9) 32.6 (8.0)
 
 30.3 (11.0) 33.5 (12.3)
 
 34.7 (14.2)
 
 29.7 (9.2) 30.6 (8.2) 36.1 (11.3) 27.7 (8.6) 31.4 (9.3) 33.8 (11.0) 
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Appendix Table 2 Cognitive test performance at baseline and after six and 12 months in the FA/B12/B6-group and the placebo-group   
 (mean (SD), unless indicated otherwise) 
 
FA/B12/B6= Folic Acid, vitamin B12 and B6; AVLT= Auditory Verbal Learning Test; SCWT-A= Stroop Colour Word Test-
Abridged; s= seconds; DSST= Digit Symbol Substitution Test; VFT= Verbal Fluency Test;
 a
 Higher score indicates better 
performance; 
b 
Lower score indicates better performance; 
c 
Median (25
th
; 75
th
 percentiles)
 Men and FA/B12/B6 Men and placebo Women and FA/B12/B6 Women and placebo 
Outcome (unit) T0 (n=44) T6 (n=44) T12 (n=43) T0 (n=41) T6 (n=41) T12 (n=38) T0 (n=34) T6 (n=34) T12 (n=28) T0 (n=33) T6 (n=33) T12 (n=29) 
MMSE 
 a, c 28 (28; 29) 28 (27; 29) 28 (27; 30) 29 (28; 29) 28 (28; 29)
 
 29 (28; 29) 29 (28; 30) 29 (28; 30) 29 (27; 30) 29 (28; 30) 28 (27; 29) 29 (27; 30) 
AVLT 1-5 (words)
 a
 31.1 (7.5) 31.3 (9.8) 29.1 (8.9) 31.7 (7.2) 35.8 (9.4)
 
 31.5 (9.3)
 
 34.9 (8.9) 35.1 (10.8) 33.7 (10.0) 34.1 (7.4) 33.7 (8.8) 31.2 (6.6) 
AVLT 6 (words)
 a
 5.6 (2.7) 5.9 (3.2) 4.9 (2.9)
 
 5.5 (2.1) 6.6 (2.8) 5.2 (2.5)
 
 6.4 (2.4) 6.8 (3.6) 5.7 (3.0) 6.0 (2.5) 5.9 (3.1) 5.4 (2.8) 
SCWT-A task 1 (s)
 b
 19.6 (3.7) 19.7 (4.3) 19.5 (4.5) 18.9 (3.7) 18.9 (4.6) 19.2 (4.1) 20.1 (5.3) 19.8 (5.2) 20.2 (4.3) 21.4 (4.6) 21.3 (4.6) 20.8 (4.8) 
SCWT-A task 2 (s)
 b
 25.8 (4.1) 26.1 (4.4) 25.8 (4.4) 24.9 (5.1) 24.7 (6.3) 25.4 (5.8) 25.3 (6.2) 25.0 (5.7) 25.0 (5.2) 27.0 (4.6) 27.0 (5.6) 25.6 (4.6) 
SCWT-A task 3 (s)
 b
 62.6 (21.1) 65.5 (29.9) 61.0 (22.4) 56.4 (16.6) 61.4 (27.5) 54.8 (12.8) 60.2 (18.1) 62.6 (25.0) 60.7 (26.3) 68.4 (23.5) 72.2 (30.1) 64.1 (24.1) 
DSST (symbols)
 a
 36.2 (11.7) 35.7 (10.2) 36.2 (12.1) 38.3 (8.7) 39.9 (9.2) 38.1 (9.1) 36.4 (10.9) 37.7 (11.6) 36.6 (10.3) 33.7 (8.9) 32.5 (10.0) 33.5 (7.7) 
VFT (words)
 a
 28.3 (10.7) 31.2 (11.2)
 
 31.8 (10.3)
 
 32.5 (9.9) 34.3 (10.6) 36.0 (13.3)
 
 28.9 (9.2) 31.2 (8.2) 33.8 (10.1) 29.0 (8.9) 30.6 (9.2) 36.7 (12.1) 
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DISCUSSION  
 
Neither the walking program nor FA/B12/B6 supplementation improved cognition in these 
community-dwelling older adults with MCI within one year. The walking program, however, was 
efficacious in improving memory in men and memory and attention in women, in those with 
better attendance.  
 
To our knowledge, this is the first intervention study with people with MCI from the general 
population. While this is a novel approach,
38;39
any benefits of the WP and FA/B6/B12-
supplementation may have been overshadowed, because of the fluctuating course of MCI in 
community-based samples.
40
 Longer interventions and follow-up may have provided better 
insight into the potential preventive effects of these interventions on cognitive decline. 
Unfortunately, this was not possible in the present study.  
 
The exact mechanisms by which aerobic exercise and vitamin supplementation may affect 
cognition are not yet known and some overlap between the hypothesized mechanisms may exist 
in terms of ‘vascular changes’. In theory, the factorial design of this trial allowed to examine 
possible interaction-effects between walking and vitamin supplementation. Unfortunately, due to 
logistical and financial constraints, it was not possible to recruit a larger sample size in order to 
have sufficient power for the examination of potential interaction. Therefore, the effect of both 
interventions was examined independently and results for one intervention were adjusted for the 
possible influence of the other.  
 
The lack of effect may have also been caused by insufficient power due to the unanticipated post-
hoc stratification for gender. Because gender was an effect modifier, reporting the results for both 
genders together would make no sense. This resulted in a decrease of statistical power to detect 
differences between FA/B12/B6-supplementation and placebo pills, and the walking program and 
the placebo activity program.  
 
Vitamin supplementation 
A benefit of FA/B12/B6 supplementation was observed only on attention in women. This is in 
line with the conclusions of recent meta-analyses, that published trials do not yet provide 
adequate evidence for an effect of supplementation with folic acid, vitamins B12 and B6, alone or 
in combination, on tests for cognitive function in people with normal or impaired cognitive 
function.
17-19;41
 A possible explanation for the lack of effect in our study may be the absence of 
screening for baseline vitamin deficiencies or hyperhomocysteinemia. However, there was no 
main intervention effect on cognition in post-hoc analyses of participants with baseline folate 
deficiency and/or hyperhomocysteinemia (n=85, data not shown). A higher dose of vitamin B 
supplementation also appears to be unwarranted, since the FA/B12/B6 supplementation 
significantly improved homocysteine and vitamin B concentrations within six months (The effects 
of exercise and folic acid, vitamins B12 and B6 on homocysteine concentrations in adults with 
mild cognitive impairment: Submitted) These changes did not result in improved cognitive 
function. A longer duration of vitamin B supplementation may however be necessary for the 
consolidation of neurological and vascular changes in order to promote cognitive function. In 
contrast to short-term interventions, Durga et al. (2007) recently observed a beneficial effect on 
cognitive performance after three years of supplementation with 800 micrograms of folic acid in 
subjects with raised homocysteine and normal vitamin B12 concentrations at baseline.
42
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Walking Program 
The lack of a main effect of exercise may have been caused by the moderate adherence to the 
exercise programs. It is important to mention that the correlation between general cognition and 
adherence was only small and non-significant. Moreover, MMSE scores at baseline and after six 
and twelve months did not differ significantly between adherent (≥ 75 % of the sessions) and 
non-adherent (< 75% of the sessions) participants (data not shown). While many previous studies 
have included data only from participants who completed the program, a strength of the present 
study is that data were analyzed according to the intention-to-treat principle, including all 
randomized participants with available data, irrespective of exercise adherence. As a result, data 
from many participants (30 out of 152) that did not attend a single exercise session were included 
in the intention-to-treat analysis. The inclusion of data from non-adherent participants may have 
underestimated the actual intervention effect in our study. The importance of adherence is 
underlined by the fact that the effect of the walking program on some of the cognitive outcomes 
increased with increasing adherence.  
 
In our study, baseline physical activity levels were relatively high. Around 80 percent of the 
women and 90 percent of the men reported being at least moderately active for 30 minutes or 
more per day. In comparison, in the general Dutch population 65 to 75 years of age, only 60 
percent of women and 70 percent of men make this claim.
43 
Despite the high self-reported 
baseline activity levels, the WP was efficacious in improving aerobic fitness compared with the 
PAP (Feasibility and Effectiveness of Two Group-Based Exercise Programs for Community-
Dwelling Older Adults with Mild Cognitive Impairment. Submitted). Since larger effects of 
exercise on cognition are expected in sedentary subjects,
5
 it is possible that a threshold physical 
activity level exists, above which additional moderate-intensity physical activity does not result 
in further cognitive benefit.  
 
It is also possible that the contrast between the programs was not large enough to induce between 
group differences. However, according to heart rate recordings, there were clear differences 
between the moderate intensity of the WP and the low intensity of the PAP. (Feasibility and 
Effectiveness of Two Group-Based Exercise Programs for Community-Dwelling Older Adults 
with Mild Cognitive Impairment. Submitted). Indeed, the use of a low-intensity placebo activity 
program with non-aerobic exercise in the present study could be seen as a strength, as it offered 
the opportunity to blind both participants and instructors to the exercise intervention, and to 
exclude the Hawthorne effect of attention.  
 
Although the rigorous design of our study (including the intention-to-treat analysis, blinding of 
participants, exercise instructors and outcome assessors, and a range of valid measurements to 
assess cognition) reduces the likelihood of bias, it may also explain the absence of beneficial 
main effects. Etnier et al. (1997)
44
 performed a thorough meta-analysis on the effect of exercise 
on cognition, and found that the effect size decreased as experimental rigor increased. It must be 
noted that this meta-analysis was published in 1997 and did not include more recent 
methodologically sound positive trials.  
 
Unfortunately, our results do not correspond with two recent meta-analyses on the effects of 
exercise on cognitive function in cognitively healthy and demented subjects, which found 
significant positive effects.
5;6
 The conclusions of these meta-analyses may have shifted to a more 
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positive view as a result of publication bias.
45
 Publication bias may arise from the tendency of 
journals to reject studies without a positive outcome, and from the fact that authors are less likely 
to submit statistically non-significant results for publication.
46
 Dissemination of both ‘positive’ 
and ‘negative’ findings is of great importance for science development as it provides better 
insight into which interventions are effective and which are not.  
 
In conclusion, our results do not support the role of vitamin B supplementation in improving 
cognitive function in people with MCI. However, our findings suggest that regular participation 
in moderate-intensity walking may improve aspects of cognition, especially memory, in 
community-dwelling people with MCI. Regular participation in moderate-intensity physical 
activity should therefore be encouraged in this population group. Future larger trials are needed to 
confirm these findings. Another direction for future research is to examine ways to increase 
exercise frequency among this population. 
 
What is already known on this topic: 
- Cognitive impairment is a public health concern, since it occurs frequently among older 
people and their number is growing  
- Aerobic exercise and vitamin B supplementation may benefit cognitive function 
- The effectiveness of these interventions has not been examined yet in community-dwelling 
people with mild cognitive impairment. 
 
What this study adds: 
Neither a moderate-intensity walking program, nor high dose vitamin B supplementation was 
effective in improving cognitive function of community-dwelling older adults with mild 
cognitive impairment within one year. The walking program, however, was efficacious in 
improving memory in men and memory and attention in women with better adherence.  
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